Skip to content

Replimune Group REPL Short-Term Investments

Short-Term Investments at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$5.79B+10.1%
CG Oncology logo
CG OncologyCGON
$1.04B+61.1%
Erasca, Inc. logo
Erasca, Inc.ERAS
$196.53M-16.0%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$513.68M-8.7%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$621M-22.9%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$222.01M+40.3%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's short-term investments?
Replimune Group (REPL) reported short-term investments of $146.19M in Q4 2025.
How has Replimune Group's short-term investments changed year-over-year?
Replimune Group's short-term investments decreased by 59.9% year-over-year, from $364.29M to $146.19M.
What is the long-term trend for Replimune Group's short-term investments?
Over 4 years (2021 to 2025), Replimune Group's short-term investments has grown at a 6.1% compound annual growth rate (CAGR), from $293.78M to $372.69M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.